Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics
Crossref DOI link: https://doi.org/10.1007/s00228-017-2403-3
Published Online: 2018-01-04
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Freise, Kevin J.
Hu, Beibei
Salem, Ahmed Hamed
Funding for this research was provided by:
AbbVie
Genentech
License valid from 2018-01-04